EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study

Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Camilla Maria Monico, Enrico Tombetti, Giovanni Maconi, Samanta Romeo, Nicole Piazza O Sed, Flavio Caprioli, Anna Maria Mazzola, Saverio Alicante, Roberto Bertè, Elisabetta Lolli und 6 weitere

Digestive Diseases and Sciences · 2024

DOI: 10.1007/s10620-024-08394-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Anna Maria Carvalhas Gabrielli und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Via Giovanni Battista Grassi, 74, 20157, Milan, MI, Italy. amcgabrielli@gmail.…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Colectomy, Piperidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor recently approved to induce and maintain remission in ulcerative colitis (UC). AIMS: Considering the number of anti-TNF non-responders, this study aims to assess the effectiveness and safety of tofacitinib in a cohort of multi-failure patients with moderate-to-severe UC at 52 weeks. METHODS: From January 2021 to March 2023, we performed a prospective multicenter study observing adult patients with moderate-to-severe UC starting tofacitinib after an anti-TNF failure for a 52-week-long period. Effectiveness and safety were assessed in terms of colectomy rate, clinical remission and response, endoscopic remission, steroid-free clinical remission, and rate of adverse events. RESULTS: We included 58 patients with UC with an age of 42 ± 14.4 years, 59% males, 96.6% left-sided or pancolitis, who were failure to a single (65.5%) or more than one anti-TNF (34.5%). Only 6 (10.3%) patients underwent colectomy. Colectomy was clinically associated with the necessity and the number of extra cycles of tofacitinib 10 mg bid at W8 (p = 0.023) and W24 (p = 0.004), and with a higher partial Mayo score at W8 (p = 0.025). At W52, clinical remission, clinical response, and steroid-free clinical remission were 53.4%, 43.1%, and 48.3%, respectively. Of 22 performed colonoscopies at W52, 11 (50%) showed endoscopic remission. Adverse events occurred in 14 (24.1%) patients, but only 2 (3.4%) led to tofacitinib discontinuation. CONCLUSIONS: In a real-life setting of patients with anti-TNF refractory UC, tofacitinib has proved to be effective in preventing colectomy and inducing clinical and endoscopic remission at 52 weeks with a good safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePyrimidinesColectomyPiperidinesHumansMaleFemaleAdultMiddle AgedProspective StudiesItalyTumor Necrosis Factor InhibitorsJanus Kinase InhibitorsRemission InductionTreatment OutcomeProtein Kinase Inhibitors

Stichwörter der Autor:innen

Biologic therapyInflammatory bowel diseaseJAK-inhibitorSurgery

Substanzen

PyrimidinesPiperidinesTumor Necrosis Factor InhibitorsJanus Kinase InhibitorsProtein Kinase Inhibitorstofacitinib

Autor:innen und Institutionen

  • Gastroenterology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Via Giovanni Battista Grassi, 74, 20157, Milan, MI, Italy. amcgabrielli@gmail.com.
  • Gastroenterology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Via Giovanni Battista Grassi, 74, 20157, Milan, MI, Italy.
  • Internal Medicine and Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
  • Gastroenterology and Digestive Endoscopy Dept, ASST Ospedale Maggiore Di Crema, Crema, Italy.
  • Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico Di Milano, Milan, Italy.

Zitieren

APA

Carvalhas Gabrielli, A. M., Ferretti, F., Monico, C. M., Tombetti, E., Maconi, G., Romeo, S., Piazza O Sed, N., Caprioli, F., Mazzola, A. M., Alicante, S., Bertè, R., Lolli, E., Scribano, M. L., Buscarini, E., Ricci, C., Carmagnola, S., Ardizzone, S., & Cannatelli, R. (2024). Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08394-w

Vancouver

Carvalhas Gabrielli AM, Ferretti F, Monico CM, Tombetti E, Maconi G, Romeo S, et al. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08394-w

BibTeX
@article{CarvalhasGabrielli2024,
  author = {Carvalhas Gabrielli, Anna Maria and Ferretti, Francesca and Monico, Camilla Maria and Tombetti, Enrico and Maconi, Giovanni and Romeo, Samanta and Piazza O Sed, Nicole and Caprioli, Flavio and Mazzola, Anna Maria and Alicante, Saverio and Bertè, Roberto and Lolli, Elisabetta and Scribano, Maria Lia and Buscarini, Elisabetta and Ricci, Chiara and Carmagnola, Stefania and Ardizzone, Sandro and Cannatelli, Rosanna},
  title = {Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  doi = {10.1007/s10620-024-08394-w}
}
Kostenlos starten →